Verastem has filed a patent for a method of treating cancer in patients with a specific KRAS G12V mutation. The method involves administering a MEK inhibitor, either alone or in combination with another agent, to effectively treat abnormal cell growth. GlobalData’s report on Verastem gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Verastem, cancer treatment biomarkers was a key innovation area identified from patents. Verastem's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treating cancer with a mek inhibitor in kras g12v mutation
A recently filed patent (Publication Number: US20230201198A1) describes methods for treating cancer in subjects with specific KRAS mutations using MEK inhibitors. The patent claims cover various scenarios, including treating subjects with KRAS G12V or KRAS G12D mutations, as well as subjects with any type of cancer who have been previously identified as having these mutations. The method involves administering an effective amount of a MEK inhibitor to the subject, which helps in treating the cancer.
The patent also includes claims related to the dosing and administration of the MEK inhibitor. It suggests that the MEK inhibitor can be dosed once a week, twice a week, once daily, or twice daily. The dosing can be carried out for at least three weeks, and in a cycle where the MEK inhibitor is administered for three weeks followed by a one-week break. The patent further specifies a range of dosages for the MEK inhibitor, from about 0.1 mg to about 100 mg, with specific values mentioned such as about 0.5 mg, about 4 mg, and about 3.2 mg. The MEK inhibitor can be administered orally.
Additionally, the patent mentions the possibility of administering an additional agent along with the MEK inhibitor. Specifically, it suggests the use of a FAK inhibitor as the additional agent. Various FAK inhibitors are listed, including defactinib, TAE226, BI-853520, GSK2256098, PF-03814735, BI-4464, VS-4718, and APG-2449. The FAK inhibitor can be dosed once daily or twice daily, with dosages ranging from about 100 mg to about 1000 mg, and specific values mentioned such as about 200 mg and about 400 mg. The FAK inhibitor can also be administered orally.
The patent covers the treatment of various types of cancer, including ovarian cancer, non-small cell lung cancer (NSCLC adenocarcinoma), uterine endometrioid carcinoma, pancreatic adenocarcinoma, colorectal adenocarcinoma, and lung adenocarcinoma. However, it specifically mentions that the method is applicable to non-small cell lung cancer.
Furthermore, the patent includes claims for treating cancer using a pan-RAF inhibitor in subjects with KRAS G12V or KRAS G12D mutations. This provides an alternative treatment option for these specific mutations.
In summary, the patent describes methods for treating cancer in subjects with specific KRAS mutations using MEK inhibitors. It also covers dosing, administration, and the possibility of combining the MEK inhibitor with a FAK inhibitor. The patent's claims encompass various scenarios and provide potential treatment options for different types of cancer.
To know more about GlobalData’s detailed insights on Verastem, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
